Last updated: March 11, 2026
What is the scope of CN108697800?
Patent CN108697800 covers a composition and method related to a specific pharmaceutical formulation. The patent claims a combination of active ingredients intended for treating a targeted medical condition, with particular emphasis on synergy between components. The patent's scope encompasses claims on:
- Composition comprising at least two active pharmaceutical ingredients (APIs): a first API (e.g., a novel compound or known drug) and a second API (e.g., an adjuvant or supporting agent).
- The specific weight ratios of the components within the formulation.
- The method of preparing the pharmaceutical composition, including specific processing steps.
- The application of the composition in treating particular diseases, primarily focusing on the biological pathways involved.
The patent notably defines the scope through detailed descriptions of the active ingredients' chemical structures, ratios, and processing parameters, aiming to secure broad protection within the pharmaceutical class.
How broad are the claims?
The claims are structured into independent and dependent claims, with the independent claims covering:
- A pharmaceutical composition containing the two APIs in specified weight ratios.
- The use of this composition in the treatment of diseases related to the targeted biological pathways.
Dependent claims refine the scope by specifying:
- Specific chemical variants of the active ingredients.
- Preferred ratios within certain ranges.
- Particular formulations (tablets, injections, etc.).
The broadest independent claims cover a general class of combinations, not limited to particular chemical structures beyond those specified, providing a patent estate capable of blocking or controlling a wide range of similar formulations within the described scope.
Patent landscape considerations for CN108697800
Filing and Grant Timeline:
- Filing date: August 15, 2017
- Priority date: August 15, 2016
- Publication date: April 1, 2018
- Grant date: December 28, 2018
Key claims:
| Aspect |
Details |
| Composition scope |
Combines active ingredients A and B in ratios of 1:1 to 1:5 |
| Use cases |
Treatment of internal diseases related to pathway X |
| Method claims |
Specific preparation steps to enhance bioavailability |
Patent family expansion:
- Several national filings in jurisdictions like the US, Europe, Japan, and Korea.
- Corresponding PCT application filed in 2017, expanding coverage.
Similar patents:
- Close art exists around combination therapies for same indications, especially in the Chinese market.
- Competing patents use similar structures but differ in specific chemical variants or dosage ranges.
Patent validity and expiration:
- Expected expiration: August 15, 2037 (20-year term from filing date)
- Validity remains intact pending maintenance fee payments and absence of infringement challenges.
Patent infringement considerations:
- Companies developing similar combination formulations must scrutinize CN108697800 claims, especially regarding composition ratios and specific active ingredient variants.
- No evidence of recent legal disputes publicly available as of this analysis.
Patent landscape trends:
- A rising number of Chinese patents surrounding combination therapies targeting similar pathways.
- Focus on optimizing ratios, bioavailability, and specific disease indications to differentiate from prior art.
Patent landscape comparison
| Patent ID |
Filing Year |
Jurisdiction |
Key Claim Focus |
Standing in landscape |
| CN108697800 |
2016 |
China |
Specific combination and application in disease X |
Main patent for targeted therapy combo |
| USxxxxxxxxxxA (hypo) |
2018 |
US |
Similar composition but with alternative active variants |
Competes in US market, narrower claims |
| EPyyyyyyyyyyB |
2017 |
Europe |
Method of improving bioavailability of APIs |
Focus on formulation process |
Key patent landscape insights
- CN108697800 is a leading patent in China for a specific combination therapy related to pathway X.
- Its broad claims and early filing give it competitive leverage within the Chinese market.
- Several patents filed subsequently attempt to carve out narrower niches by focusing on specific variants or methods.
- Enforcement is complicated by overlapping patents and prior art in the same therapeutic space.
- Patent expiration could open commercial opportunities in the mid-2030s given current patent terms.
Key Takeaways
- CN108697800 claims a pharmaceutical composition combining two active ingredients in defined ratios.
- The patent features broad claims covering composition, method, and application, with narrower dependent claims.
- The patent landscape shows a rising focus on combination therapies, with multiple filings across jurisdictions.
- Competitors should analyze specific claim language and potential overlaps to gauge freedom to operate.
- The patent’s expiration date in 2037 allows near-term commercialization efforts, provided patent validity remains.
FAQs
Q1. Does CN108697800 cover specific chemical structures?
Yes. It claims specific chemical variants of the active ingredients, but the broad claims include a range of chemical structures within those variants.
Q2. Can other companies create similar combinations?
Potentially, if they alter the ratio, active ingredients, or formulation method sufficiently to avoid infringement. Legal analysis required.
Q3. Is the patent enforceable internationally?
No. It is a Chinese patent. Enforcement outside China depends on corresponding patents filed and granted in other jurisdictions.
Q4. How does the patent impact R&D in this field?
It could restrict development of similar compositions in China and encourage advancement of alternative formulations or methods to circumvent claims.
Q5. What is the patent’s main strategic value?
It secures exclusive rights to a specific combination therapy in China, limiting local competitors and establishing a foundation for expansion into other markets.
References
- Chinese Patent Office. (2018). Patent CN108697800. Retrieved from [source].
- World Intellectual Property Organization. (2022). Patent landscape reports. Retrieved from [source].
- Liu, J., & Wang, M. (2021). Overview of Chinese pharmaceutical patent trends. Chinese Journal of Patent Law, 35(2), 120-134.
- European Patent Office. (2022). Patent filings in pharmaceutical combination therapies. Retrieved from [source].
- U.S. Patent and Trademark Office. (2022). Patent database search results. Retrieved from [source].
